Ventavis® (Iloprost): Evaluation of Inhaled Iloprost Effects Using the Breelib™ Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 01 Dec 2017
At a glance
- Drugs Iloprost (Primary)
- Indications Pulmonary arterial hypertension
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- Acronyms VENTASTEP
- Sponsors Bayer
- 28 Nov 2017 Planned primary completion date changed from 15 Nov 2018 to 15 Dec 2018.
- 28 Nov 2017 Planned initiation date changed from 15 Nov 2017 to 15 Dec 2017.
- 24 Oct 2017 Planned primary completion date changed from 30 Sep 2018 to 15 Nov 2018.